Neurocrine Biosciences target price raised to $185 from $183 by Morgan Stanley
NBIX•Morgan Stanley raised its target price for Neurocrine Biosciences to $185 from $183.
Related News
Tempus AI target price raised to $120 from $100
TEM•
Apollo Global misses Q3 revenue estimates, declares dividend
APO•
Compass Pathways Q3 net loss narrows on lower R&D charges
CMPS•
Marathon Petroleum Q3 adjusted EPS beats estimates on higher crack spreads
MPC•
ADT Q3 diluted EPS from continuing operations rises 18% to $0.20
ADT•